A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
December 15, 2016
End Date
December 14, 2021
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
December 15, 2016
End Date
December 14, 2021